Contaminants in heparin: Review of the literature, molecular profiling, and clinical implications

Clinical and Applied Thrombosis/Hemostasis

Volumn 17, Issue 2, 2011, Pages 126-135

  Ramacciotti, Eduardo ^a   Clark, Melanie ^a   Sadeghi, Nasir ^a   Hoppensteadt, Debra ^a   Thethi, Indermohan ^a   Gomes, Marise ^a   Fareed, Jawed ^a  

^a LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

anticoagulants; clinical pharmacology; heparins

Indexed keywords

CARBON 14; CHONDROITIN SULFATE; DERMATAN SULFATE; HEPARIN; HEPARIN COFACTOR II; KALLIKREIN; PREKALLIKREIN; THROMBOCYTE FACTOR 4; ANTICOAGULANT AGENT; SEROTONIN;

ANAPHYLAXIS; ANGIONEUROTIC EDEMA; ANTICOAGULATION; BLEEDING; COMPLEMENT SYSTEM; DRUG CONTAMINATION; DRUG SCREENING; HEPARIN INDUCED THROMBOCYTOPENIA; HUMAN; HYPOTENSION; IMMUNE DEFICIENCY; IMMUNE RESPONSE; MOLECULAR WEIGHT; MULTIPLE ORGAN FAILURE; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; PROTHROMBIN TIME; REVIEW; SEROTONIN RELEASE; THROMBIN TIME; THROMBOCYTE ACTIVATION; ANIMAL; CHEMICALLY INDUCED DISORDER; COMPLEMENT ACTIVATION; DRUG EFFECT; ENZYME ACTIVATION; METABOLISM; THROMBOCYTOPENIA;

ANIMALS; ANTICOAGULANTS; CHONDROITIN SULFATES; COMPLEMENT ACTIVATION; DERMATAN SULFATE; DRUG CONTAMINATION; ENZYME ACTIVATION; HEPARIN; HUMANS; PLATELET FACTOR 4; PREKALLIKREIN; SEROTONIN; THROMBOCYTOPENIA;

EID: 79952776987     PISSN: 10760296     EISSN: None     Source Type: Journal    
DOI: 10.1177/1076029610392214     Document Type: Review

References (35)

1. Hoppensteadt DA, Wahi R., Adiguzel C., et al. Contaminant in the recalled unfractionated heparin preparations: where is the problem ? Clin Appl Thromb Hemost. 2008 ; 14 (3). 261-266. (Pubitemid 351871947)
2. Ramacciotti E., Wahi R., Messmore HL Contaminated heparin preparations, severe adverse events and the contact system. Clin Appl Thromb Hemost. 2008 ; 14 (4). 489-491.
3. Blossom DB, Kallen AJ, Patel PR, et al. Outbreak of adverse reactions associated with contaminated heparin. N Engl J Med. 2008 ; 359 (25). 2674-2684.
4. Schwartz LB Heparin comes clean. N Engl J Med. 2008 ; 358: 2505-2509. (Pubitemid 351793026)
5. Fareed J., Ahluwalia M., Wahi R., Ramaccioti E., Hoppensteadt D., Bick RL Contaminants in heparins continue to be unfolded. Int Angiol. 2008 ; 27 (6). 457-461.
6. Fareed J. Biological profile of the hyper/oversulfated chondroitin sulfate contaminant isolated from recalled heparin. Semin Thromb Hemost. 2008 ; 34 (1). 119-127.
7. Guerrini M., Zhang Z., Shriver Z., et al. Orthogonal analytical approaches to detect potential contaminants in heparin. Proc Natl Acad Sci U S A. 2009 ; 106 (40). 16956-16961.
8. Kishimoto TK, Viswanathan K., Ganguly T., et al. Contaminated heparin associated with adverse clinical events and activation of the contact system. N Engl J Med. 2008 ; 358 (23). 2457-2467. (Pubitemid 351793019)
9. Guerrini M., Beccati D., Shriver Z., et al. Oversulfated chondroitin sulfate is a contaminant in heparin associated with adverse clinical events. Nat Biotechnol. 2008 ; 26 (6). 669-675. (Pubitemid 351824692)
10. Bigler P., Brenneisen R. Improved impurity fingerprinting of heparin by high resolution (1)H NMR spectroscopy. J Pharm Biomed Anal. 2009 ; 49 (4). 1060-1064.
11. Volpi N., Maccari F., Linhardt RJ Quantitative capillary electrophoresis determination of oversulfated chondroitin sulfate as a contaminant in heparin preparations. Anal Biochem. 2009 ; 388 (1). 140-145.
12. Beyer T., Diehl B., Randel G., et al. Quality assessment of unfractionated heparin using 1H nuclear magnetic resonance spectroscopy. J Pharm Biomed Anal. 2008 ; 48 (1). 13-19.
13. Neville GA, Mori F., Holme KR, Perlin AS Monitoring the purity of pharmaceutical heparin preparations by high-field 1H-nuclear magnetic resonance spectroscopy. J Pharm Sci. 1989 ; 78 (2). 101-104. (Pubitemid 19079822)
14. Sitkowski J., Bednarek E., Bocian W., Kozerski L. Assessment of oversulfated chondroitin sulfate in low molecular weight and unfractioned heparins diffusion ordered nuclear magnetic resonance spectroscopy method. J Med Chem. 2008 ; 51 (24). 7663-7665.
15. Wang L., Buchanan S., Meyerhoff ME Detection of high-charge density polyanion contaminants in biomedical heparin preparations using potentiometric polyanion sensors. Anal Chem. 2008 ; 80 (24). 9845-9847.
16. Spencer JA, Kauffman JF, Reepmeyer JC, et al. Screening of heparin API by near infrared reflectance and Raman spectroscopy. J Pharm Sci. 2009 ; 98 (10). 3540-3547.
17. Trehy ML, Reepmeyer JC, Kolinski RE, Westenberger BJ, Buhse LF Analysis of heparin sodium by SAX/HPLC for contaminants and impurities. J Pharm Biomed Anal. 2009 ; 49 (3). 670-673.
18. Tami C., Puig M., Reepmeyer JC, et al. Inhibition of Taq polymerase as a method for screening heparin for oversulfated contaminants. Biomaterials. 2008 ; 29 (36). 4808-4814.
19. Clark M., Hoppensteadt D., Walenga J., et al. Molecular profiling of heparinase-I resistant glycosaminoglycans in contaminated heparins. Comparative studies with uncontaminated heparin and porcine oversulfated chondroitin sulfate. Int Angiol. 2008 ; 27 (5). 370-376.
20. Bairstow S., McKee J., Nordhaus M., Johnson R. Identification of a simple and sensitive microplate method for the detection of oversulfated chondroitin sulfate in heparin products. Anal Biochem. 2009 ; 388 (2). 317-321.
21. Hu P., Fang L., Chess EK Source-induced fragmentation of heparin, heparan, and galactosaminoglycans and application. Anal Chem. 2009 ; 81 (6). 2332-2343.
22. Greinacher A., Warkentin TE Contaminated heparin. N Engl J Med. 2008 ; 359 (12). 1291-1292 ; ; author reply 3.
23. Ganong WF Cardiovascular homeostasis in health and disease. In: Naggi A, ed. Review of Medical Physiology, 2 2 nd ed. New York: McGraw Hill ; 2002: 256-259.
24. Deitch EA Multiple organ failure. Pathophysiology and potential future therapy. Ann Surg. 1992 ; 216 (2). 117-134.
25. Li B., Suwan J., Martin JG, et al. Oversulfated chondroitin sulfate interaction with heparin-binding proteins: new insights into adverse reactions from contaminated heparins. Biochem Pharmacol. 2009 ; 78 (3). 292-300.
26. Warkentin TE Heparin-induced thrombocytopenia. Hematol Oncol Clin North Am. 2007 ; 21 (4). 589-607, v. (Pubitemid 47102555)
27. Adiguzel C., Bansal V., Litinas E., et al. Increased prevalence of antiheparin platelet factor 4 antibodies in patients may be due to contaminated heparin. Clin Appl Thromb Hemost. 2009 ; 15 (2). 145-151.
28. Walenga J. HIT NATF 2008 NAFTonline ; 2008.
29. Kohl J. Anaphylatoxins and infectious and non-infectious inflammatory diseases. Mol Immunol. 2001 ; 38 (2-3). 175-187. (Pubitemid 32786775)
30. Ember JA, Hugli TE Complement factors and their receptors. Immunopharmacology. 1997 ; 38 (1-2). 3-15. (Pubitemid 28049959)
31. Haas PJ, van Strijp J. Anaphylatoxins: their role in bacterial infection and inflammation. Immunol Res. 2007 ; 37 (3). 161-175. (Pubitemid 47577440)
32. Lambrecht BN An unexpected role for the anaphylatoxin C5a receptor in allergic sensitization. J Clin Invest. 2006 ; 116 (3). 628-32. (Pubitemid 43326869)
33. Wills-Karp M. Complement activation pathways: a bridge between innate and adaptive immune responses in asthma. Proc Am Thorac Soc. 2007 ; 4 (3). 247-251. (Pubitemid 47036443)
34. Wills-Karp M., Koehl J. New insights into the role of the complement pathway in allergy and asthma. Curr Allergy Asthma Rep. 2005 ; 5 (5). 362-369. (Pubitemid 41683979)
35. Tollefsen D. Anticoagulants and HIT. Washington University in St. Louis Hematology/Oncology Grand Rounds 2008-2009. St. Louis: Washington University in St. Louis ; 2008: 1-36.